Medical Condition News

RSS

Scientists uncover new role for key cancer protein

Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.

10 Jun 2011

Study finds brain differences in preschool children with symptoms of ADHD

In a study published today in the Clinical Neuropsychologist, researchers from the Kennedy Krieger Institute found differences in the brain development of preschool children with symptoms of Attention-deficit/Hyperactivity Disorder (ADHD).

10 Jun 2011

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

10 Jun 2011

Study identifies sharp rise in Parkinson's prevalence in Israel from 2000 to 2007

In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, Israeli researchers report that by tracking pharmacy purchases of anti-Parkinson drugs they could estimate the number of Parkinson's disease (PD) cases in a large population.

10 Jun 2011

Eli Lilly, Synthes collaborate to develop osteoinductive products

Synthes, Inc. and Eli Lilly and Company today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.

10 Jun 2011

NKI, Agendia and MD Anderson collaborate for colorectal cancer research

Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment options of colorectal cancer patients.

10 Jun 2011

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.

10 Jun 2011

Exercise protects against silent stroke: Study

Strokes can cause brain damage by cutting off blood flow to the brain. But unlike major strokes, recognizable by symptoms such as weakness on one side of the body and trouble speaking, so-called silent strokes by definition go unnoticed. Symptoms can include subtle memory and mobility problems, as well as an increased risk for future strokes, according to the American Academy of Neurology. Silent strokes are also different from mini-strokes, which are noticeable but last only for minutes or hours.

9 Jun 2011

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

9 Jun 2011

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Toxin known to affect humans identified in endangered Hawaiian monk seal

Researchers from NOAA have discovered a potent and highly-debilitating toxin in the endangered Hawaiian monk seal, a first-of-its-kind chemical finding that is now prompting investigations of other marine mammals in the state.

9 Jun 2011

University of Mississippi grants ChromaDex global rights to pterostilbene

ChromaDex Corp. and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.

9 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

Lund researchers create nerve cells from human skin

A research breakthrough has proven that it is possible to reprogram mature cells from human skin directly into brain cells, without passing through the stem cell stage. The unexpectedly simple technique involves activating three genes in the skin cells; genes which are already known to be active in the formation of brain cells at the foetal stage.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Synaptophysin controls replacement of vesicles

A University of Wisconsin-Madison research team has solved a 25-year mystery that may lead to better treatments for people with learning deficits and mental retardation.

9 Jun 2011

Tips for preventing outdoor home-related injury: AANS

The nail-gun neck injury and treatment incurred by a 25-year-old carpenter described in the Journal of Neurosurgery: Spine article might read like an oddity, but nail guns are actually a common form of penetrating low-velocity injury. What made this case unique was that the patient incurred a penetrating wound to the cervical spine by a barbed nail lodged in close proximity to the right vertebral artery.

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

What starts as burning, numbness, pain, and/or tingling in the feet, or hands in some can turn into a debilitating condition. Peripheral Neuropathy (PN), one of the largest and most common neurodegenerative disorders, affects more than 20 million Americans of all races and ethnic backgrounds.

9 Jun 2011

Medical Condition News

Scientists uncover new role for key cancer protein

Study finds brain differences in preschool children with symptoms of ADHD

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Study identifies sharp rise in Parkinson's prevalence in Israel from 2000 to 2007

Eli Lilly, Synthes collaborate to develop osteoinductive products

NKI, Agendia and MD Anderson collaborate for colorectal cancer research

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Exercise protects against silent stroke: Study

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Toxin known to affect humans identified in endangered Hawaiian monk seal

University of Mississippi grants ChromaDex global rights to pterostilbene

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

Lund researchers create nerve cells from human skin

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Synaptophysin controls replacement of vesicles

Tips for preventing outdoor home-related injury: AANS

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News